Loading...
Loading...
MNPR| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 1,788.8K |
| Operating I/L | -1,788.8K |
| Other Income/Expense | 73.5K |
| Interest Income | 73.5K |
| Pretax | -1,715.3K |
| Income Tax Expense | -1,788.8K |
| Net Income/Loss | -1,715.3K |
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics. Its lead product candidate, Validive, is in Phase 2b/3 clinical trial for the prevention of severe oral mucositis in patients with oropharyngeal cancer. The company is also developing Camsirubicin for advanced soft tissue sarcoma, MNPR-101 for various cancers, MNPR-101 RIT for cancer and severe COVID-19, and MNPR-202 for resistant cancers. Monopar has collaborations for the development of its products and potential treatments. The company generates revenue through the development and potential commercialization of its therapeutic products for cancer treatment.
